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A bs tr ac t 
Background
We hypothesized that in patients with stable coronary artery disease and stenosis, 
percutaneous coronary intervention (PCI) performed on the basis of the fractional 
flow reserve (FFR) would be superior to medical therapy.
Methods
In 1220 patients with stable coronary artery disease, we assessed the FFR in all 
stenoses that were visible on angiography. Patients who had at least one stenosis 
with an FFR of 0.80 or less were randomly assigned to undergo FFR-guided PCI plus 
medical therapy or to receive medical therapy alone. Patients in whom all stenoses 
had an FFR of more than 0.80 received medical therapy alone and were included in 
a registry. The primary end point was a composite of death from any cause, nonfa-
tal myocardial infarction, or urgent revascularization within 2 years.
Results
The rate of the primary end point was significantly lower in the PCI group than in 
the medical-therapy group (8.1% vs. 19.5%; hazard ratio, 0.39; 95% confidence in-
terval [CI], 0.26 to 0.57; P<0.001). This reduction was driven by a lower rate of ur-
gent revascularization in the PCI group (4.0% vs. 16.3%; hazard ratio, 0.23; 95% CI, 
0.14 to 0.38; P<0.001), with no significant between-group differences in the rates of 
death and myocardial infarction. Urgent revascularizations that were triggered by 
myocardial infarction or ischemic changes on electrocardiography were less frequent 
in the PCI group (3.4% vs. 7.0%, P = 0.01). In a landmark analysis, the rate of death or 
myocardial infarction from 8 days to 2 years was lower in the PCI group than in the 
medical-therapy group (4.6% vs. 8.0%, P = 0.04). Among registry patients, the rate of 
the primary end point was 9.0% at 2 years.
Conclusions
In patients with stable coronary artery disease, FFR-guided PCI, as compared with 
medical therapy alone, improved the outcome. Patients without ischemia had a fa-
vorable outcome with medical therapy alone. (Funded by St. Jude Medical; FAME 2 
ClinicalTrials.gov number, NCT01132495.)
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The benefit of percutaneous coro-nary intervention (PCI) as an initial treat-ment strategy in patients with stable coro-
nary artery disease remains controversial.1-3 The 
potential result from revascularization depends 
on the extent and the degree of myocardial is-
chemia.4,5 A fractional flow reserve (FFR) value 
of 0.80 or less (i.e., a drop in maximal blood flow 
of 20% or more caused by stenosis), as measured 
with the use of a coronary pressure wire during 
catheterization, indicates the potential of a ste-
nosis to induce myocardial ischemia.6-8
In such cases, robust clinical-outcome data 
favor FFR-guided revascularization, as compared 
with revascularization guided by angiography 
alone.9-16 In previous trials comparing PCI with 
medical therapy alone in patients with stable 
coronary artery disease,1,2 investigators did not 
use FFR guidance or contemporary drug-eluting 
stents.
In the Fractional Flow Reserve versus Angiog-
raphy for Multivessel Evaluation 2 (FAME 2) tri-
al, we investigated whether contemporary PCI 
plus medical therapy would be superior to 
medical therapy alone in patients with stable 
coronary artery disease and functionally signifi-
cant stenoses, as determined by the FFR. This 
report describes the prespecified 2-year results 
for the primary outcome.
Me thods
Patients
We enrolled patients with clinically stable coro-
nary artery disease involving up to three vessels 
(as determined on angiography) that was suitable 
for treatment with PCI. The inclusion and exclu-
sion criteria have been described previously.17 
Using a centralized randomization method, we 
assigned patients who had at least one stenosis in 
a major coronary artery with an FFR of 0.80 or 
less to undergo FFR-guided PCI (with the use of 
the PressureWire Certus or PressureWire Aeris, 
St. Jude Medical) plus medical therapy (PCI 
group) or to receive medical therapy alone 
(medical-therapy group). Patients with an FFR of 
more than 0.80 in all stenoses received medical 
therapy alone and were included in a registry. All 
patients provided informed written consent. The 
study protocol is available with the full text of 
this article at NEJM.org.
Study Design and Oversight
We conducted this open-label, randomized trial 
at 28 sites in Europe and North America. The 
trial was approved by the institutional review 
board at each participating center. The members 
of the steering committee designed the study 
without involvement of the sponsor, St. Jude 
Medical. The sponsor was involved in the collec-
tion and source verification of the data but not in 
the conduct of the trial. An independent data and 
safety monitoring board oversaw the trial. The 
members of the steering committee had full ac-
cess to all the data in the study, wrote the manu-
script, and made the decision to submit it for 
publication.
Study Treatments 
Patients were prescribed daily aspirin, a beta-
blocker (alone or in combination with a calcium-
channel blocker, a long-acting nitrate, or both), 
an angiotensin-converting–enzyme inhibitor or 
angiotensin-receptor blocker, and atorvastatin 
alone or in combination with ezetimibe to 
achieve a low-density lipoprotein cholesterol level 
of less than 70 mg per deciliter (1.8 mmol per 
liter). Among patients in the medical-therapy 
group and the registry patients, the prescription 
of clopidogrel was left to the discretion of the 
treating clinician. Among patients in the PCI 
group, all stenoses with an FFR of 0.80 or less 
were treated with second-generation drug-elut-
ing stents. These patients received clopidogrel (at 
a dose of 75 mg per day) for at least 12 months in 
addition to standard medical therapy. Smokers 
were counseled regarding smoking cessation, 
and patients with diabetes were referred to a spe-
cialist in order to optimize their treatment.
Study End Points and Follow-up
The primary end point was a composite of death 
from any cause, nonfatal myocardial infarction, 
or unplanned hospitalization leading to urgent 
revascularization within 2 years. Fifty percent of 
registry patients were randomly selected to be fol-
lowed up in the same manner as the study pa-
tients. For each outcome event, a detailed narra-
tive was produced. All events were adjudicated by 
an independent clinical-events committee whose 
members were unaware of the assigned treatment.
Revascularization was considered to be ur-
gent when a patient was admitted to the hospital 
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with persistent or increasing symptoms (with or 
without changes in the ST segment or T wave or 
elevated biomarker levels) and the revasculariza-
tion procedure was performed during the same 
hospitalization. All urgent revascularizations 
were adjudicated by two independent cardiolo-
gists, who were unaware of the assigned treat-
ment, to determine the type of trigger (myocar-
dial infarction, electrocardiographic evidence of 
ischemic changes, or clinical features only) and 
the severity of angina (according to the criteria 
of the Canadian Cardiovascular Society [CCS]) 
that led to the procedure.
Adverse Events
Serious adverse events were defined as any event 
that resulted in death or was life-threatening, re-
quired hospitalization or prolongation of a hos-
pital stay, or resulted in persistent or substantial 
disability. Also included were all protocol-speci-
fied clinical end-point events.
Statistical Analysis
The trial was powered to determine the superior-
ity of FFR-guided PCI plus medical therapy over 
medical therapy alone with respect to the pri-
mary end point at 2 years. We estimated that the 
cumulative incidence of the primary end point 
would be 12.6% in the PCI group18-20 and 18.0% 
in the medical-therapy group,1 which would cor-
respond to a relative risk reduction of 30% in the 
PCI group. We determined that the enrollment of 
816 patients in each study group would provide a 
power of more than 84% to detect a relative risk 
reduction of 30% at a two-sided type I error rate 
of 0.05.
We used the Mantel–Cox method to calculate 
hazard ratios and 95% confidence intervals for 
between-group comparisons of clinical out-
comes and the log-rank test to calculate corre-
sponding P values. All patients were included in 
the intention-to-treat analysis. We constructed 
Kaplan–Meier curves for the primary end point 
and its components. In exploratory analyses, we 
separately plotted cumulative urgent-revascular-
ization events triggered by myocardial infarc-
tion, unstable angina with evidence of ischemia 
on electrocardiography, or clinical features only, 
stratified according to the CCS class, and used 
the Mantel–Cox method to calculate hazard ra-
tios with 95 confidence intervals and log-rank 
tests to calculate P values.
We performed separate analyses according to 
a landmark (cutoff) point of 7 days after random-
ization, with hazard ratios calculated separately 
for events that occurred within 7 days and those 
that occurred between 8 days and the end of fol-
low-up at 2 years. For each type of event, data for 
patients were censored at the time of the first 
event — for example, data for a patient who had 
an event that contributed to the primary compos-
ite end point during the first 7 days were censored 
at the time of the event and excluded from the 
analysis of subsequent years after the landmark 
point. Landmark analyses were accompanied by a 
chi-square test for interaction between treatment 
effect and time (first 7 days vs. subsequent peri-
od). All analyses were performed by two indepen-
dent statisticians at an academic clinical-trials 
unit (CTU Bern, University of Bern).
R esult s
Patients
Among 1220 patients who were enrolled between 
May 15, 2010, and January 15, 2012, a total of 
888 had at least one stenosis with an FFR of 0.80 
or less in a large epicardial artery. These patients 
were randomly assigned to undergo FFR-guided 
PCI plus medical therapy (447 patients) or to re-
ceive medical therapy alone (441 patients). In the 
remaining 332 registry patients, all stenoses that 
were visible on angiography had an FFR of more 
than 0.80. On the basis of the highly significant 
between-group difference in the primary end 
point, patient recruitment was halted on January 
15, 2012, after the randomization of 54% of the 
patients in the initially planned study sample 
(Fig. S1 in the Supplementary Appendix, avail-
able at NEJM.org). The characteristics of the pa-
tients at baseline, which have been described 
previously,17 were well balanced between the two 
treatment groups (Table S1 in the Supplementary 
Appendix). Among the 888 patients, 1601 steno-
ses were eligible for PCI on the basis of angiog-
raphy, whereas 1304 stenoses were eligible for 
PCI on the basis of an FFR of 0.80 or less, with a 
mean (±SD) FFR of 0.64±0.13 (range, 0.19 to 0.80).
Primary End Point
At 2 years, at least one primary outcome event 
had occurred in 36 patients (8.1%) in the PCI 
group and in 86 patients (19.5%) in the medical-
therapy group (hazard ratio in the PCI group, 
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0.39; 95% confidence interval [CI], 0.26 to 0.57; 
P<0.001) (Table 1, and Table S2 in the Supple-
mentary Appendix). In the registry group, at least 
one event in the primary end point occurred in 
15 patients (9.0%), with little difference between 
the PCI group and registry patients (hazard ratio, 
0.90; 95% CI, 0.49 to 1.64; P = 0.72) but a large 
difference between the medical-therapy group 
and registry patients (hazard ratio, 2.34; 95% CI, 
1.35 to 4.05; P = 0.002) (Table S2 and Fig. S2 in 
the Supplementary Appendix).
Landmark Analyses
Within 7 days after randomization, there were 
more primary end-point events in the PCI group 
than in the medical-therapy group (2.2% vs. 
Table 1. Clinical Events and Triggers of Urgent Revascularization.*
Variable
PCI  
(N = 447)
Medical Therapy 
(N = 441)
Hazard Ratio  
(95% CI)† P Value‡ 
no. (%)
Primary end point 36 (8.1) 86 (19.5) 0.39 (0.26–0.57) <0.001
Death from any cause 6 (1.3) 8 (1.8) 0.74 (0.26–2.14) 0.58
Myocardial infarction 26 (5.8) 30 (6.8) 0.85 (0.50–1.45) 0.56
Urgent revascularization 18 (4.0) 72 (16.3) 0.23 (0.14–0.38) <0.001
Death or myocardial infarction 29 (6.5) 36 (8.2) 0.79 (0.49–1.29) 0.35
Other end points
Death from cardiac causes 3 (0.7) 3 (0.7) 0.99 (0.20–4.90) 0.99
Revascularization 
Any 36 (8.1) 179 (40.6) 0.16 (0.11–0.22) <0.001
Nonurgent 18 (4.0) 117 (26.5) 0.13 (0.08–0.22) <0.001
Stroke 7 (1.6) 4 (0.9) 1.74 (0.51–5.94) 0.37
Definite or probable stent thrombosis 7 (1.6) 2 (0.5) 3.48 (0.72–16.8) 0.10
Triggers of urgent revascularization according to  
Canadian Cardiovascular Society class§
Any trigger
All classes 18 (4.0) 72 (16.3) 0.23 (0.14–0.38) <0.001
0, I, or II 4 (0.9) 7 (1.6) 0.56 (0.16–1.93) 0.35
III 3 (0.7) 20 (4.5) 0.14 (0.04–0.49) <0.001
IV 11 (2.5) 47 (10.7) 0.22 (0.11–0.42) <0.001
Myocardial infarction or changes on ECG
All classes 15 (3.4) 31 (7.0) 0.47 (0.25–0.86) 0.01
0, I, or II 3 (0.7) 4 (0.9) 0.74 (0.17–3.31) 0.69
III 2 (0.4) 7 (1.6) 0.28 (0.06–1.35) 0.09
IV 10 (2.2) 21 (4.8) 0.46 (0.22–0.98) 0.04
Clinical features only
All classes 3 (0.7) 43 (9.8) 0.07 (0.02–0.21) <0.001
0, I, or II 1 (0.2) 3 (0.7) 0.33 (0.03–3.17) 0.31
III 1 (0.2) 14 (3.2) 0.07 (0.01–0.53) 0.001 
IV 1 (0.2) 27 (6.1) 0.03 (0.00–0.26) <0.001
* ECG denotes electrocardiography, and PCI percutaneous coronary intervention.
† Hazard ratios are for the PCI group as compared with the medical-therapy group.
‡ P values were calculated with the use of the log-rank test.
§ Patients could have more than one event. The Canadian Cardiovascular Society grades the severity of angina as follows: 
class I, angina only during strenuous or prolonged physical activity; class II, slight limitation, with angina only during 
vigorous physical activity; class III, symptoms with activities of everyday living (moderate limitation); and class IV, in-
ability to perform any activity without angina or angina at rest (severe limitation).
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Figure 1. Kaplan–Meier Curves for the Landmark Analyses.
Shown are the cumulative incidences of the primary end point (a composite of death from any cause, nonfatal myocar-
dial infarction, or urgent revascularization) (Panel A) and of death or myocardial infarction (Panel B) in the two study 
groups, stratified on the basis of a landmark point at 7 days after randomization (vertical dashed line). Hazard ratios 
for PCI versus medical therapy were calculated separately for events that occurred within 7 days and those that occurred 
between 8 days and the end of follow-up at 2 years. Data for the first 7 days are not included in the period after 7 days. 
The insets show the data for days 0 to 7 on an expanded y axis. P values for interaction were calculated from tests of 
heterogeneity between time periods. Hazard ratios below 1.00 denote a lower incidence of the primary end point in the 
PCI group than in the medical-therapy group.
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0.9%; hazard ratio, 2.49; 95% CI, 0.78 to 8.00; 
P = 0.11) (Fig. 1A, and Table S3 in the Supplemen-
tary Appendix). Six out of 10 primary end-point 
events in the PCI group were periprocedural 
myocardial infarctions. During the period from 
8 days to 2 years after randomization, patients 
undergoing PCI had a 44% relative risk reduction 
for the composite of death or myocardial infarc-
tion (4.6% vs. 8.0%; hazard ratio, 0.56; 95% CI, 
0.32 to 0.97; P = 0.04) (Fig. 1B) and a 79% relative 
risk reduction for urgent revascularization (3.6% 
vs. 15.6%; hazard ratio, 0.21; 95% CI, 0.12 to 
0.37; P<0.001), with a significant interaction be-
tween treatment and time for the composite of 
death or myocardial infarction (P = 0.002 for inter-
action) but not for urgent revascularization 
(P = 0.34 for interaction).
Urgent Revascularization
The between-group difference in the primary end 
point was driven by a 77% reduction in the need 
for urgent revascularization in the PCI group, as 
compared with the medical-therapy group (4.0% 
vs. 16.3%; hazard ratio, 0.23; 95% CI, 0.14 to 
0.38; P<0.001) (Table 1). Figure 2 shows the cu-
mulative numbers of unplanned rehospitaliza-
tions with urgent revascularization according to 
the type of trigger and angina class over time. 
Eighteen urgent revascularizations were per-
formed in 18 patients in the PCI group (2.1 events 
per 100 patient-years), whereas 79 revasculariza-
tions were performed in 72 patients in the medi-
cal-therapy group (10.4 events per 100 patient-
years).
In these 90 patients in the two study groups, 
revascularizations were triggered by a myocar-
dial infarction in 28 patients (31%), by unstable 
angina with ischemic changes on electrocardi-
ography in 18 patients (20%), and by clinical 
features only in the remaining 44 patients (49%), 
with a predominance of CCS class IV angina, 
regardless of the trigger. There were significant 
differences between the PCI group and the 
medical-therapy group with respect to urgent 
revascularizations triggered by a myocardial in-
farction or ischemic electrocardiographic chang-
es (3.4% vs. 7.0%; hazard ratio, 0.47; 95% CI, 
0.25 to 0.86; P = 0.01) and those triggered by CCS 
class IV angina (2.5% vs. 10.7%; hazard ratio, 
0.22; 95% CI, 0.11 to 0.42; P<0.001). Figure 3 
shows the cumulative incidence of revasculariza-
tion for any reason.
Other End Points
After 2 years, 179 patients (40.6%) in the medi-
cal-therapy group had crossed over to undergo 
PCI, whereas 36 patients (8.1%) in the PCI group 
had undergone repeat revascularization (hazard 
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Figure 2. Urgent Revascularizations, According to Type of Trigger.
Cumulative events of urgent revascularization are shown for patients in the 
PCI group (Panel A) and those in the medical-therapy group (Panel B), 
according to whether the procedure was triggered by myocardial infarction, 
electrocardiographic (ECG) changes, or clinical features only and according 
to the severity of angina at presentation, as indicated by Canadian 
Cardiovascular Society (CCS) class.
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITAET BERN on November 6, 2014. For personal use only. No other uses without permission. 
 Copyright © 2014 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 371;13 nejm.org september 25, 20141214
ratio, 0.16; 95% CI, 0.11 to 0.22; P<0.001). Table 
S2 in the Supplementary Appendix presents a 
comparison of end points for patients in the two 
study groups and the 166 registry patients who 
were followed for up to 2 years; 20 registry pa-
tients (12.0%) crossed over to undergo PCI. Fig-
ure S3 in the Supplementary Appendix presents 
stratified analyses of the primary end point ac-
cording to the characteristics of the patients at 
baseline. The reduction from baseline in the per-
centage of patients with angina of CCS grade II, 
III, or IV was greater among patients in the PCI 
group than among those in the medical-therapy 
group and those in the registry group at all time 
points during 2 years of follow-up (Fig. S4 in the 
Supplementary Appendix). After 2 years, 69% of 
patients were still receiving a combination of aspi-
rin, beta-blockers, and statins (Table S4 in the 
Supplementary Appendix).
Serious Adverse Events
At least one clinical event or other serious adverse 
event was reported in 151 patients (33.8%) in the 
PCI group and in 232 patients (52.6%) in the med-
ical-therapy group (hazard ratio, 0.55; 95% CI, 
0.44 to 0.67; P<0.001) (Table 1, and Table S5 in the 
Supplementary Appendix). The same percentage 
of patients in the two groups (17.2%) had noncar-
diovascular serious adverse events, including clin-
ical events (hazard ratio, 1.00; 95% CI, 0.73 to 
1.38; P = 0.98), whereas serious cardiovascular ad-
verse events (defined as death from cardiac causes, 
myocardial infarction, stent thrombosis, any re-
vascularization, or any other cardiovascular seri-
ous adverse event) were reported in 110 patients in 
the PCI group as compared with 204 patients in 
the medical-therapy group (24.6% vs. 46.3%; haz-
ard ratio, 0.45; 95% CI, 0.36 to 0.57; P<0.001).
Discussion
In our study involving patients with stable coro-
nary artery disease and stenosis, the rate of the 
primary end point (death, myocardial infarction, 
or urgent revascularization at 2 years) among 
those who underwent FFR-guided PCI with con-
temporary drug-eluting stents was less than half 
the rate among patients who received medical 
therapy alone. Urgent revascularizations trig-
gered by a myocardial infarction or ischemic 
changes on electrocardiography were half as fre-
quent in the PCI group as in the medical-therapy 
group. Although there was no significant be-
tween-group difference in the overall rate of 
death or myocardial infarction, patients who un-
derwent PCI, as compared with those who re-
ceived medical therapy alone, had a significant 
reduction in the rate of death or myocardial in-
farction after the initial 7 days following ran-
domization.
More than 25% of patients with stable coro-
nary artery disease who were scheduled to un-
dergo PCI on the basis of clinical and angio-
graphic data had no stenosis with an FFR value 
of 0.80 or less and were thus unlikely to have 
had ischemia. These patients had a favorable 
clinical outcome at 2 years with medical therapy 
alone, a finding that is similar to results in pa-
tients with at least one clinically significant 
stenosis who were treated with PCI plus medical 
therapy. The degree of angina at 2 years was 
significantly lower in the PCI group than in the 
medical-therapy group, even though almost 50% 
of patients who were initially assigned to the 
medical-therapy group had died, had had a myo-
cardial infarction, or had undergone revascular-
ization.
In daily clinical practice, less than half of 
patients undergo noninvasive stress testing be-
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Figure 3. Kaplan–Meier Curves for Total Revascularizations.
Shown are the cumulative incidences of total revascularizations in the two 
study groups during the 2-year study period. Hazard ratios and the corre-
sponding 95% confidence intervals are based on a Mantel–Cox comparison 
of revascularizations with PCI versus medical therapy alone, and the P val-
ues were calculated with the use of a log-rank test. Additional details are 
provided in Figure S5 in the Supplementary Appendix. 
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fore elective PCI,21 and the decision to perform 
revascularization is based primarily on the an-
giographic appearance of a stenosis. There is a 
growing awareness of the poor accuracy of coro-
nary angiography for identifying lesions respon-
sible for myocardial ischemia and the inaccuracy 
of noninvasive stress testing in patients with 
multivessel coronary artery disease.22,23 In our 
randomized trial, we enrolled only patients with 
an FFR of 0.80 or less in at least one large epi-
cardial artery. In contrast to all previous trials 
comparing PCI with medical therapy in patients 
with stable coronary artery disease, this FFR-
driven selection process excluded patients with-
out clinically significant ischemia, who are 
known to be at lower risk than are those with 
ischemia. The inclusion of these low-risk pa-
tients in previous trials limited the potential for 
showing any benefit from PCI. In our study, the 
measurement of FFR in patients with multivessel 
coronary artery disease allowed for the determi-
nation of which lesions were hemodynamically 
significant. Such lesions were shown to benefit 
from PCI, as compared with hemodynamically 
nonsignificant stenoses, for which PCI is unnec-
essary or even harmful.9,10 The resolution of 
ischemia in the patients treated with FFR-guided 
PCI probably explains the similar event rates 
among registry patients who had coronary artery 
disease and similar baseline characteristics but 
who received medical therapy alone because they 
had no ischemia-producing lesions.
Multiple studies have suggested that peripro-
cedural infarctions rarely have an effect on the 
long-term prognosis for patients undergoing 
PCI,24,25 whereas spontaneous infarctions are 
predictive of an increased risk of death. In our 
study, the rate of death or myocardial infarction 
was significantly higher in the medical-therapy 
group than in the PCI group after the initial 7 
days following randomization because of a 
higher rate of spontaneous myocardial infarc-
tion in the medical-therapy group.
The primary end point of our study included 
not only death and myocardial infarction but 
also unplanned hospitalization for urgent revas-
cularization. The definition of urgent revascu-
larization was stringent in order to distinguish 
urgent from nonurgent procedures. Severe an-
gina was present in more than 90% of patients 
who underwent urgent revascularization, and in 
more than 40% of these patients, there was an 
increase in biomarkers or dynamic changes on 
electrocardiography, which are criteria for per-
forming PCI according to both American and 
European guidelines.26,27 Therefore, urgent re-
vascularization in our study should be consid-
ered a failure of the treatment to which the pa-
tient has been assigned.
In contrast to previous trials comparing PCI 
with medical therapy,1,2 we used second-genera-
tion drug-eluting stents.18-20 This factor may 
partially explain the improved outcome in pa-
tients with stable coronary artery disease who 
were treated with PCI as compared with the 
outcome in the medical-therapy group.28,29 
Our trial has several limitations. First, enroll-
ment was interrupted early after interim analy-
ses by the data and safety monitoring board 
disclosed a large excess of primary end-point 
events in the medical-therapy group. Second, 
patients and treating physicians were aware of 
study-group assignments. It is possible that the 
awareness of the presence of a functionally sig-
nificant stenosis influenced the decision of the 
physician or the patient during follow-up. Yet, 
the fact that the group of registry patients with 
angiographically significant coronary artery dis-
ease had a lower number of events than those in 
the medical group suggests that the awareness 
of having an unstented coronary blockage can-
not explain the high event rates among patients 
in the medical-therapy group. Moreover, the 
significantly higher rates of death and myocar-
dial infarction that occurred more than 7 days 
after randomization in the medical-therapy 
group than in the PCI group and the registry 
group cannot be explained by the lack of blind-
ing. Third, stenoses were located in large coro-
nary arteries and the mean FFR value was 0.64, 
which suggests both profound and extensive 
ischemia. Thus, these results should not be ex-
tended to patients with smaller vascular areas 
at risk.
In conclusion, among patients with stable 
coronary artery disease and ischemia, as shown 
by the presence of at least one stenosis with an 
FFR of 0.80 or less in a large epicardial artery, 
the clinical outcome at 2 years was improved by 
FFR-guided PCI with second-generation drug-
eluting stents plus the best available medical ther-
apy, as compared with medical therapy alone. In 
patients without hemodynamically significant 
stenosis, the best available medical therapy alone 
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was associated with an excellent 2-year clinical 
outcome, regardless of the angiographic appear-
ance of the stenoses.
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